Affordable Access

Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma.

Authors
Type
Published Article
Journal
Journal of the National Medical Association
0027-9684
Publisher
Elsevier
Publication Date
Volume
97
Issue
10
Pages
1414–1416
Identifiers
PMID: 16353663
Source
Medline
License
Unknown

Abstract

The adverse events were few with cumulative doses as high as 1,360 mg/m2. These cases show that pegylated liposomal doxorubicin may be a promising agent in recurrent ovarian carcinoma. We recognize the limitations of our data. The results need to be confirmed in a larger group of patients.

Statistics

Seen <100 times